SUSTAINED SUPPRESSION OF TESTOSTERONE PRODUCTION BY THE LUTEINISING-HORMONE RELEASING-HORMONE AGONIST BUSERELIN IN PATIENTS WITH ADVANCED PROSTATE CARCINOMA-Reference-Cited by-同舟云学术

SUSTAINED SUPPRESSION OF TESTOSTERONE PRODUCTION BY THE LUTEINISING-HORMONE RELEASING-HORMONE AGONIST BUSERELIN IN PATIENTS WITH ADVANCED PROSTATE CARCINOMA

Published:1982-05 Issue:8281 Volume:319 Page:1097-1099
ISSN:0140-6736
Container-title:The Lancet
language:en
Short-container-title:The Lancet

Author:

Borgmann V.,Hardt W.,Schmidt-Gollwitzer M.,Adenauer H.,Nagel R.

Publisher

Elsevier BV

Subject

General Medicine

Reference13 articles.

1. Potent inhibitory activity of [D-Leu-deS-GLY-NH210] LHRH ethylamide on LH, hCG and PRL testicular receptor levels in the rat;Auclair;Endocrinology,1977

2. Evaluation of the gonadotrophic responsiveness of the pituitary to acute and prolonged administration of LH/FSH-releasing hormone (LH-RH) in normal females and males;Pinto;Acta Endocrinol,1979

3. Pharmacology of LH-RH and its analogues;Sandow,1981

4. Hypothalamic-pituitary-testicular function in rats after supraphysiological doses of a highly active LRH analogue (buserelin);Sandow;Acta Endocrinol,1980

5. LH- and FSH response to long-term application of LH-RH analogue in normal males;Wiegelmann;Hormone Metab Res,1977

Cited by 115 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Follicle-Stimulating Hormone Exacerbates Cardiovascular Disease in the Presence of Low or Castrate Testosterone Levels;JACC: Basic to Translational Science;2023-12

2. Design, Synthesis and Cytotoxicity Evaluation of Novel Indole Derivatives Containing Benzoic Acid Group as Potential AKR1C3 Inhibitors;Chemistry & Biodiversity;2020-11-24

3. Kombinierte Systemtherapie beim metastasierten hormonsensitiven Prostatakarzinom: Was? Wann? Bei wem?;Der Urologe;2020-04-09

4. The role of ketoconazole in current prostate cancer care;Nature Reviews Urology;2018-08-28

5. AKR1C3 Inhibitor KV-37 Exhibits Antineoplastic Effects and Potentiates Enzalutamide in Combination Therapy in Prostate Adenocarcinoma Cells;Molecular Cancer Therapeutics;2018-06-11